Stock price when the opinion was issued
EPS of $0.08 missed expectations of $0.086 and revenues of $91.1M beat estimates of $83.64M. This is the second consecutive quarter of disappointing results, and while it trades at a reasonable valuation of 13.3X forward earnings, its high and growing debt levels are a concern. Its valuation has been lower in the past, and so there is room for multiple contraction here. Given its high debt load and long-term declining earnings, we would feel comfortable taking some gains off the table here. With debt levels creeping higher, we feel this can begin to erode its profits and cash flow.
Unlock Premium - Try 5i Free
EPS of 9c crushed estimate of 6.3c; Revenue of $102.2M beat estimates of $84.9M. EBITDA of $26.5M beat estimates by 13%. Revenue rose a robust 39%, EBITDA rose 37%. Commentary was good, with the company focused on both organic growth and acquisitions, and it continues to buyback stock. Debt is still on the high side but these results were solid. The stock is down 14% this year, but we think these results should get it a bit of attention. As a small, cyclical company there remains risks here, and it is more expensive at 15X earnings than many others. But we would see it as a reasonable, though higher risk, buy for small cap investors only.
Unlock Premium - Try 5i Free